Recommendations for the Deprescribing of Psychotropic Medications

Through this Consensus Statement, the Task Force identified circumstances in which the selective elimination of certain psychotropic medications may be clinically indicated. Empirical trials are needed to assess the implementation of deprescribing protocols and gauge their safe, effective, and acceptable outcomes.

Authors

Institutions

Publication Details

Journal
JAMA Network Open
Published
2026-02-25
DOI
https://doi.org/10.1001/jamanetworkopen.2026.0043
Citations
1
Primary Topic
Schizophrenia research and treatment
Type
article
Field-Weighted Citation Impact
33.12

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Recommendations for the Deprescribing of Psychotropic Medications

Matthew Macaluso, Michael Gitlin, Anita H. Clayton, Lori L. Davis et al.
1 citations
JAMA Network Open
Schizophrenia research and treatment
33.12
article

Recommendations for the Deprescribing of Psychotropic Medications

Matthew Macaluso, Michael Gitlin, Anita H. Clayton, Lori L. Davis, Gerard Sanacora, George I. Papakostas, José M. Rubio, Dan V. Iosifescu, Lawrence J. Cohen, Gayla Y. Paschall, Holly A. Swartz, Sandra Steingard, Marlene P. Freeman, Swapnil Gupta, Richard C. Shelton, Goodman D, Gin S Malhi, Arifulla Khan, Mauricio Tohen, M. Sajatovic, P. Gorwood, Philip B. Mitchell, R. W. Kupka, R. S. McIntyre, A. H. Young, Michael Berk, Mark A. Frye, Rajnish Mago, Carlos A. Zarate, Leslie Citrome, Michael E. Thase, Joseph Zohar, Toshi A. Furukawa, Roy H. Perlis, Andrew A. Nierenberg, Joseph F. Goldberg, Manish K. Jha, Scott T. Aaronson, Christoph U. Correll, Siegfried Kasper, John M. Kane, Joshua D. Rosenblat, Eduard Vieta
article en
1 citations

Abstract

Through this Consensus Statement, the Task Force identified circumstances in which the selective elimination of certain psychotropic medications may be clinically indicated. Empirical trials are needed to assess the implementation of deprescribing protocols and gauge their safe, effective, and acceptable outcomes.

JAMA Network OpenVol. 9(2)
University of Vermont (US), University of North Texas (US), Nathan Kline Institute for Psychiatric Research (US), National Institutes of Health (US), Northwell Health (US), Barwon Health (AU), Yale New Haven Hospital (US), University Health Network (CA), Feinstein Institute for Medical Research (US), Mayo Clinic (US), Harvard University (US), Johns Hopkins University (US), Inserm (FR), University of California, Los Angeles (US), University of North Texas Health Science Center (US), University of New Mexico (US), University of Pittsburgh (US), New York Medical College (US), King's College London (GB), University of Toronto (CA), SUNY Upstate Medical University (US), Université Paris Cité (FR), Kyoto University (JP), University Hospitals of Cleveland (US), Sheba Medical Center (IL), Royal North Shore Hospital (AU), Massachusetts Mental Health Center (US), Instituto de Salud Carlos III (ES), University of North Texas System (US), UNSW Sydney (AU), University of Oxford (GB), Massachusetts General Hospital (US), Sheppard Pratt Health System (US), Behavioral Health Systems (US), Northwest Clinical Research Center (US), Southwestern Medical Center (US), Donald & Barbara Zucker School of Medicine at Hofstra/Northwell (US), VA Hudson Valley Health Care System (US), Bellevue Hospital Center (US), Baim Institute for Clinical Research (US), Hospital Clínic de Barcelona (ES), Northern Sydney Local Health District (AU), Centre Hospitalier Sainte-Anne (FR), Kyoto University of Education (JP), Institut de Psychiatrie et Neurosciences de Paris (FR), Amsterdam University Medical Centers (NL), University School (US), National Institute of Mental Health (US), Consorci Institut D'Investigacions Biomediques August Pi I Sunyer (ES), Wellcome Centre for Ethics and Humanities (GB), Medical Research Network (US), Zucker Hillside Hospital (US), University of Virginia (US), New York University (US), Case Western Reserve University (US), Universitat de Barcelona (ES), Medical University of Vienna (AT), Charité - Universitätsmedizin Berlin (DE), University of Pennsylvania (US), The University of Texas Southwestern Medical Center (US), Stanford University (US), Icahn School of Medicine at Mount Sinai (US)
U.S. Department of Veterans Affairs, Massachusetts General Hospital, Yale University, Syracuse University, State University of New York, Johns Hopkins University, University of Texas Southwestern Medical Center, University of North Texas, Northwell Health, York University, King's College London, University of Oxford, Institut National de la Santé et de la Recherche Médicale, University of New South Wales, Deakin University, Universität Wien, Medizinische Universität Wien, Barwon Health Foundation, National Institutes of Health, School of Medicine, Stanford University, State University of New York Upstate Medical University, Institute of Psychiatry, Psychology and Neuroscience, King’s College London, NYU Grossman School of Medicine, Feinstein Institutes for Medical Research, Faculty of Medicine and Health, University of Sydney
Good health and well-being
Openalex Percentile: Top 1%
Schizophrenia research and treatment
33.12
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.